First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.
Zacks.com on MSN3d
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung CancerStudy investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...
Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% ...
The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...
Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 ...
The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...
Johnson & Johnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option ...
J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback